Photodynamic immunotherapy using ADU-S100-modified nanoparticles to treat triple-negative breast cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch. Gynecol. Obstet. 293(2), 247–269 (2016).
  Medline CASGoogle Scholar
• 2. Callmann CE, Cole LE, Kusmierz CD, Huang Z, Horiuchi D, Mirkin CA. Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer. Proc. Natl Acad. Sci. USA 117(30), 17543–17550 (2020).
  Medline CASGoogle Scholar
• 3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65(1), 5–29 (2015).
  MedlineGoogle Scholar
• 4. Adam L, Kassouf W, Dinney CP. Clinical applications for targeted therapy in bladder cancer. Urol. Clin. North Am. 32(2), 239–246 (2005).
  MedlineGoogle Scholar
• 5. Sun X, Zhang Y, Li J et al. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. Nat. Nanotechnol. 16(11), 1260–1270 (2021). • The study explained the potential of cyclic dinucleotide STING gene agonists in the immunotherapy of cancer.
  Medline CASGoogle Scholar
• 6. Wang J, Li P, Yu Y et al. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science 367(6480), eaau0810 (2020).
  Medline CASGoogle Scholar
• 7. Kelly PN. The cancer immunotherapy revolution. Science 359(6382), 1344–1345 (2018).
  Medline CASGoogle Scholar
• 8. Corrales L, Glickman LH, McWhirter SM et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11(7), 1018–1030 (2015).
  Medline CASGoogle Scholar
• 9. Jiang M, Chen P, Wang L et al. cGAS-STING, an important pathway in cancer immunotherapy. J. Hematol. Oncol. 13(1), 81 (2020).
  Medline CASGoogle Scholar
• 10. Deng L, Xu Z, Li F et al. Insights on the cGAS-STING signaling pathway during herpesvirus infections. Front. Immunol. 13, 931885 (2022).
  Medline CASGoogle Scholar
• 11. Chattopadhyay S, Liu YH, Fang ZS et al. Synthetic immunogenic cell death mediated by intracellular delivery of STING agonist nanoshells enhances anticancer chemo-immunotherapy. Nano Lett. 20(4), 2246–2256 (2020).
  Medline CASGoogle Scholar
• 12. Shae D, Becker KW, Christov P et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat. Nanotechnol. 14(3), 269–278 (2019).
  Medline CASGoogle Scholar
• 13. Li A, Yi M, Qin S, Chu Q, Luo S, Wu K. Prospects for combining immune checkpoint blockade with PARP inhibition. J. Hematol. Oncol. 12(1), 98 (2019).
  MedlineGoogle Scholar
• 14. Lemos H, Mohamed E, Huang L et al. STING promotes the growth of tumors characterized by low antigenicity via IDO activation. Cancer Res. 76(8), 2076–2081 (2016).
  Medline CASGoogle Scholar
• 15. Gou S, Liu W, Wang S et al. Engineered nanovaccine targeting Clec9a⁺ dendritic cells remarkably enhances the cancer immunotherapy effects of STING agonist. Nano Lett. 21(23), 9939–9950 (2021). • The study revealed the importance of activating dendritic cells in STING agonist-based cancer immunotherapy.
  Medline CASGoogle Scholar
• 16. Chattopadhyay S, Hu CMJ. Nanomedicinal delivery of stimulator of interferon genes agonists: recent advances in virus vaccination. Nanomedicine 15(29), 2883–2894 (2020).
  CASGoogle Scholar
• 17. Leach DG, Dharmaraj N, Piotrowski SL et al. STINGel: controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy. Biomaterials 163, 67–75 (2018).
  Medline CASGoogle Scholar
• 18. Li S, Luo M, Wang Z et al. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nat. Biomed. Eng. 5(5), 455–466 (2021).
  Medline CASGoogle Scholar
• 19. Liang J, Wang H, Ding W et al. Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity. Sci. Adv. 6(35), eabc3646 (2020).
  Medline CASGoogle Scholar
• 20. Wen J, Wu D, Qin M et al. Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice. Nat. Biomed. Eng. 3(9), 706–716 (2019).
  Medline CASGoogle Scholar
• 21. Yang W, Zhang F, Deng H et al. Smart nanovesicle-mediated immunogenic cell death through tumor microenvironment modulation for effective photodynamic immunotherapy. ACS Nano 14(1), 620–631 (2020). •• The study revealed the advantages of combining photodynamic therapy with cancer immunotherapy.
  Medline CASGoogle Scholar
• 22. Liu WL, Zou MZ, Liu T et al. Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells. Nat. Commun. 10(1), 3199 (2019).
  MedlineGoogle Scholar
• 23. Liu X, Liu Y, Li X et al. ER-targeting PDT converts tumors into in situ therapeutic tumor vaccines. ACS Nano 16(6), 9240–9253 (2022).
  Medline CASGoogle Scholar
• 24. Dai J, Dong X, Liu R et al. A peptide-AIEgen nanocomposite mediated whole cancer immunity cycle-cascade amplification for improved immunotherapy of tumor. Biomaterials 285, 121528 (2022).
  Medline CASGoogle Scholar
• 25. Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumor immune evasion. Nat. Rev. Immunol. 20(4), 209–215 (2020).
  Medline CASGoogle Scholar
• 26. Timperi E, Gueguen P, Molgora M et al. Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer. Cancer Res. 82(18), 3291–3306 (2022).
  Medline CASGoogle Scholar
• 27. Crunkhorn S. Crossing the blood–brain barrier. Nat. Rev. Drug Discov. 20(10), 740 (2021).
  Google Scholar
• 28. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumors with combination immunotherapies. Nat. Rev. Drug Discov. 18(3), 197–218 (2019).
  Medline CASGoogle Scholar
• 29. Yue W, Chen L, Yu L et al. Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumor growth and metastases in mice. Nat. Commun. 10(1), 2025 (2019).
  MedlineGoogle Scholar
• 30. Deng G, Sun Z, Li S et al. Cell-membrane immunotherapy based on natural killer cell membrane coated nanoparticles for the effective inhibition of primary and abscopal tumor growth. ACS Nano 12(12), 12096–12108 (2018).
  Medline CASGoogle Scholar
• 31. Zhang Y, Chen H, Wang H et al. A synergistic cancer immunotherapy nano-system for preventing tumor growth. Chem. Eng. J. 380, 122472 (2020).
  CASGoogle Scholar
• 32. Lu K, He C, Guo N et al. Chlorin-based nanoscale metal-organic framework systemically rejects colorectal cancers via synergistic photodynamic therapy and checkpoint blockade immunotherapy. J. Am. Chem. Soc. 138(38), 12502–12510 (2016).
  Medline CASGoogle Scholar
• 33. Chen Q, Xu L, Liang C, Wang C, Peng R, Liu Z. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat. Commun. 7, 13193 (2016).
  Medline CASGoogle Scholar
• 34. Moore E, Clavijo PE, Davis R et al. Established T cell-inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1 pathway blockade. Cancer Immunol. Res. 4(12), 1061–1071 (2016).
  Medline CASGoogle Scholar
• 35. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1), 1–10 (2013).
  MedlineGoogle Scholar
• 36. Wang S, Campos J, Gallotta M et al. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8⁺ T cells. Proc. Natl Acad. Sci. USA 113(46), E7240–E7249 (2016).
  Medline CASGoogle Scholar
• 37. Duan X, Chan C, Han W, Guo N, Weichselbaum RR, Lin W. Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. Nat. Commun. 10(1), 1899 (2019).
  MedlineGoogle Scholar
• 38. Kiyohara E, Tanemura A, Nishioka M et al. Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study. Cancer Immunol. Immunother. 69(6), 1131–1140 (2020).
  Medline CASGoogle Scholar
• 39. Li W, Yang J, Luo L et al. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat. Commun. 10(1), 3349 (2019).
  MedlineGoogle Scholar
• 40. Chen H, Luan X, Paholak HJ et al. Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy. Nanomedicine 15(1), 77–92 (2020).
  CASGoogle Scholar
• 41. Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175(2), 313–326 (2018).
  Medline CASGoogle Scholar
• 42. Tsukamoto H, Komohara Y, Tomita Y et al. Aging-associated and CD4 T-cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events. Proc. Natl Acad. Sci. USA 119(29), e2205378119 (2022).
  Medline CASGoogle Scholar
• 43. Liu W, Zou M, Liu T et al. Expandable immunotherapeutic nanoplatforms engineered from cytomembranes of hybrid cells derived from cancer and dendritic cells. Adv. Mater. 31(18), 1900499 (2019).
  Google Scholar